Ultragenyx Pharmaceutical Inc. Cash Flow Statement
RARE / Health Care|14 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
Ultragenyx Pharmaceutical Inc. used $466M in operating cash flow and negative free cash flow of $472M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$575.0M | -$569.0M | -$607.0M | -$707.4M | -$402.7M | -$197.6M | -$302.1M | -$197.6M | -$145.6M | -$59.8M | -$145.6M | -$59.8M | -$35.1M | -$16.3M |
| Depreciation & Amortization | $35.0M | $36.0M | $26.0M | $18.2M | $8.5M | $19.5M | $5.8M | $19.5M | $1.4M | $684.0K | $1.4M | $684.0K | $444.0K | $313.0K |
| Operating Cash Flow | -$466.0M | -$414.0M | -$475.0M | -$380.5M | -$345.4M | -$290.6M | -$253.8M | -$290.6M | -$106.0M | -$44.6M | -$106.0M | -$44.6M | -$31.2M | -$12.5M |
| Capital Expenditures | $6.0M | $7.0M | $44.0M | $116.1M | $24.8M | $4.1M | $2.8M | $4.1M | $5.0M | $2.1M | $5.0M | $2.1M | $407.0K | $1.1M |
| Free Cash Flow | -$472.0M | -$421.0M | -$519.0M | -$496.6M | -$370.2M | -$294.6M | -$256.6M | -$294.6M | -$110.9M | -$46.8M | -$110.9M | -$46.8M | -$31.6M | -$13.6M |
| FCF Margin | -70.1% | -75.2% | -119.6% | -136.7% | -357.0% | -572.2% | -9825.3% | -572.2% | -83407.5% | -275194.1% | - | - | - | - |